

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

INSIDE INFORMATION UNUSUAL TRADING VOLUME AND PRICE MOVEMENTS RESUMPTION OF TRADING

This announcement is published by SSY Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company have noted unusual movement in the trading volume and price of the shares of the Company (the “**Shares**”) today.

The Directors believe the increase in the trading volume and fluctuation in the price of the Shares were due to recent media news, which reported that, Li Lanjuan, a member of the Chinese Academy of Engineering and a member of the high-level expert group of the National Health Commission of the People’s Republic of China (the “**National Health Commission**”), announced the latest research results in the treatment of novel coronavirus (2019-nCoV) infected pneumonia in Wuhan, China. Li Lanjuan suggested including Abidol and Darunavir in the National Health Commission’s “Diagnosis and Treatment Program for Novel Coronavirus Infection (Trial Version 6)”. The Group owns a leading company that produces Abidol bulk pharmaceuticals and preparations in China. The Directors believe that, at the time of issue of this announcement, Li Lanjuan’s suggestions as reported in media news have not yet been confirmed to be adopted by the National Health Commission or to be included in the National Health Commission’s “Diagnosis and Treatment Program for Novel Coronavirus Infection (Trial Version 6)” and the Company cannot guarantee that this would happen soon or at all. As stated in the Company’s announcement dated 29 January 2020, for better prevention and control of the latest novel coronavirus (2019-nCoV) epidemic, green channels for direct network procurement of the first batch of related preventive and control drugs have been opened or the related preventive and control drugs have been included under the list of emergency procurements in provinces and municipals of China. Abidol Capsule, the Group’s

antiviral drug, has been admitted to either Catalogs of Products for Epidemic Prevention and Control or Green Channels for Preventive and Control Drugs in 18 provinces, and another 11 provinces would complete the admission work by the same way. Abidol has been included in China's National Medical Insurance Catalog and the list of clinically recommended drugs for antiviral influenza issued by China's National Health Commission for the first time in year 2019. At the time of issue of this announcement, Abidol Capsule has been admitted to either Catalogs of Products for Epidemic Prevention and Control or Green Channels for Preventive and Control Drugs in 22 provinces.

Having made such enquiry with respect to the Company as is reasonable in the circumstances, the Board confirm that, save as disclosed in this announcement, it is not aware of any reason that caused the aforesaid trading volume and price movement or of any other information which must be announced to avoid a false market in the Company's securities or of any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

This announcement is made by the order of the Company. The Board collectively and individually accepts responsibility for the accuracy of this announcement.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

At the request of the Company, trading in the Shares on the Stock Exchange was halted with effect from 2:34 p.m. on 5 February 2020 pending the release of this announcement. The Company has applied to the Stock Exchange for resumption of trading in the shares of the Company with effect from 9:00 a.m. on 6 February 2020.

By order of the Board
Chow Hing Yeung
Company Secretary

Hong Kong, 5 February 2020

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.